https://orcid.org/0000-0002-2398-6189
Figures & data
Figure 1 Study profile of this retrospective study.
Table 1 Baseline Characteristics of the 67 Patients with Previously Immunotherapy Treated Advanced NSCLC
Figure 2 Waterfall plot for the best change in target lesion among the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration (Blue columns represent PR, yellow columns represent SD and red columns represent PD during the best overall response).
Figure 3 Progression-free survival of the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration.
Figure 4 Overall survival of the 67 patients with previously immunotherapy treated advanced NSCLC who received anlotinib plus PD-1 blockades administration.
Figure 5 Comparison of overall survival in the 67 patients with advanced NSCLC who received anlotinib plus PD-1 blockades administration according to the response status of previous immunotherapy.
Table 2 Safety Profile of the 67 Patients with Previously Immunotherapy Treated Advanced NSCLC Who Received Anlotinib Plus PD-1 Blockades